The company combines two types of immune cells. One delivers a rapid, powerful initial attack to clear many cancer cells but doesn't persist. The other cell type remains longer to "clean up" any remaining cancerous cells, creating a more comprehensive and durable response.
Most cell therapies target a single antigen on cancer cells. Luminary engineers its cells to recognize three different receptors. The therapy only needs one of the three to be present to work, making it significantly harder for cancer cells to mutate and "escape" the treatment.
While CAR-T therapies achieve about a 50% cure rate for blood cancers, early data shows they are achieving up to an 80% cure rate in autoimmune disorders. This suggests the technology's greatest impact may lie beyond oncology, transforming the treatment of chronic diseases.
Current cell therapies are so complex and expensive—requiring a patient's own cells—that they are only available to 20% of the people who could benefit. This massive accessibility gap is the primary driver for companies to develop "off-the-shelf" solutions using healthy donor cells.